News | November 11, 2021
Hester Biosciences to acquire 50 % stake in Thrishool Exim, Tanzania
The consideration for the acquisition is US $ 2.25 million
The consideration for the acquisition is US $ 2.25 million
The company has enabled a transformation across three core areas with an investment target of US $ 150 million
The order strengthens the company’s position in the East African market
The acquisition was expected to be completed in eight weeks, and it would have provided it with a foothold in the US $ 48 billion global animal health market
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The company has already embarked upon significant expansion in Turkey
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Subscribe To Our Newsletter & Stay Updated
